-
EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight
22 Apr 2024 17:00 GMT
… EGFR inhibitors, specifically TARCEVA (erlotinib) and IRESSA … Additionally, second-generation medications such as GILOTRIF … clinical trials, visit @ EGFR Inhibitor Treatment Drugs EGFR … Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, …
-
October - December 2023 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
04 Feb 2024 08:45 GMT
… labels that contribute to wrong drug errors
FDA is evaluating the need … (afatinib)
Iressa (gefitinib)
Tarceva (erlotinib)
Cardiac failure
FDA is evaluating the need … (ezetimibe and simvastatin)
Zetia (ezetimibe)
Drug-induced liver injury
The “Postmarketing …
-
AstraZeneca’s Tagrisso maintains momentum in NSCLC with FLAURA2 results
19 Apr 2024 15:46 GMT
… Tagrisso received US Food and Drug Administration (FDA) approval in combination with … below form
By GlobalData
The trial demonstrated strong progression-free survival … , and Roche’s Tarceva for first-line treatment of metastatic disease in …
-
Treatment with EGFR inhibitors in lung cancer patients tied to increased risk of new-onset keratitis: JAMA
16 Jan 2024 02:10 GMT
… prevent severe complications or treatment disruptions.
"Over … did not take these drugs (HR 1.520),… EGFR inhibitors -- including erlotinib (Tarceva), gefitinib (Iressa), afatinib ( … and 2023. Exposures included treatment with epidermal growth factor …
-
Long Island Biotechnology: New York’s $150 Million Shot In the Arm
09 Jan 2024 17:09 GMT
… lease and maintain a biotech research center that would … – OSI Pharmaceuticals, which had developed Tarceva, a lung-cancer treatment. OSI, … Tarceva was approved by the U.S. Food and Drug … of behavioral science, bioelectronics medicine, cancer, health system …
-
Global Lung Cancer Drugs Market Forecast 2024-2033 – Market Size, Drivers, Trends, And Competitors
27 Dec 2023 16:45 GMT
… Drugs Market Segments
• By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs … Some of the possible treatments for lung cancer include … of drugs include Gemzar, paraplatin, Taxotere, navelbine, avastin, Tarceva, Iressa …
-
Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches
21 Dec 2023 04:45 GMT
… drug delivery systems for lung cancer treatment. The trials … 10.3390/pharmaceutics11030129
61. Eek D … drug-delivery systems for protein and peptide biopharmaceuticals. Trends in biotechnology. Trends Biotechnol … ®) and Erlotinib (Tarceva®) vs single agent …
-
Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer
02 Nov 2023 12:09 GMT
… the biotech industry in the fields of translational medicine, clinical trial … I to III clinical trials and global development partnerships. … and Genentech's Rituxan®, Tarceva® and Raptiva® programs. Dr. … in 2024 for the treatment of multiple solid tumors. …
-
A Drug–Drug Interaction Study to Evaluate the Impact of Simvastatin and Itraconazole on Erlotinib Pharmacokinetics in Rats by UPLC-MS/MS
18 Oct 2023 07:23 GMT
… induced by anticancer drugs. Thus, their treatments are frequently … Animal Center of Hebei Medical University (Laboratory animal … erlotinib (OSI-774, Tarceva) alone or in combination … Erlotinib and Vemurafenib In Combination Trial) Study. Clin Cancer …
-
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
04 Oct 2023 23:12 GMT
… prior clinical trial combining REQORSA with Tarceva® (erlotinib) for the treatment of late … three clinical trials evaluating the Company's lead drug candidate, REQORSA … Track Designation from the FDA for the treatment of that patient population …